Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Levetiracetam
Drug ID BADD_D01265
Description Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Indications and Usage Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Marketing Status approved
ATC Code N03AX14
DrugBank ID DB01202
KEGG ID D00709
MeSH ID D000077287
PubChem ID 5284583
TTD Drug ID D0E1XL
NDC Product Code 76494-528; 36998-5960; 0904-7265; 58032-0132; 66174-0044; 16729-064; 25021-780; 27808-263; 31722-537; 42385-956; 42385-957; 43063-499; 43063-617; 43485-102; 44567-501; 47335-573; 47335-576; 50090-1333; 50090-2456; 50405-302; 51224-013; 51672-4137; 51672-4143; 55150-177; 60687-668; 61919-559; 62135-548; 63739-019; 63739-787; 66689-030; 67296-1486; 67877-770; 67877-771; 68180-112; 68180-118; 69102-105; 70518-3317; 71930-064; 72205-037; 76282-248; 80705-101; 55111-870; 65862-245; 72643-025; 82623-501; 13668-015; 13668-017; 14789-110; 16571-789; 16571-790; 27808-264; 0121-4799; 43485-103; 43547-223; 43547-345; 44567-503; 51672-4142; 60687-657; 63187-360; 63739-158; 63739-411; 64980-362; 67296-1248; 68001-405; 0409-2011; 68382-168; 69102-106; 70518-1772; 70518-3742; 70518-3765; 71205-880; 0615-7979; 72205-095; 12666-0014; 28877-5950; 36998-0117; 51927-0088; 57572-0034; 64220-192; 65372-1148; 72640-004; 16714-537; 16729-067; 27808-266; 42385-954; 0143-9574; 43485-104; 50474-597; 51672-4136; 61919-552; 63629-4137; 63629-8315; 64980-364; 64980-365; 65862-247; 65862-250; 66689-029; 68001-113; 68083-152; 68084-882; 68084-893; 69367-332; 70860-602; 71093-144; 71335-0748; 71335-2098; 0615-7978; 71930-063; 72189-190; 64980-363; 65162-685; 65841-703; 65841-704; 66689-028; 67457-265; 67457-266; 68083-154; 68180-114; 68382-165; 68788-7430; 70518-1998; 72189-229; 76494-529; 82009-123; 0904-7124; 62512-0030; 65862-246; 65862-261; 65862-315; 75834-246; 13668-014; 16714-310; 16714-357; 16729-065; 24689-106; 0143-9673; 47133-574; 50228-473; 60429-349; 63629-4675; 0378-5615; 65162-538; 66689-102; 67877-769; 68084-859; 68180-113; 0409-1886; 0472-0235; 70518-1827; 71205-728; 71205-881; 71335-0139; 71335-0702; 72205-096; 72485-106; 76494-531; 82009-122; 36998-5950; 38779-2900; 51927-0155; 64220-152; 71901-605; 81414-001; 16729-066; 31722-539; 42385-955; 43547-454; 50228-470; 50405-303; 55111-181; 63739-795; 67877-768; 68001-403; 68071-4508; 68083-153; 68084-870; 68180-099; 68788-7884; 70518-1921; 71930-065; 72205-120; 72865-188; 76282-246; 76494-530; 36998-5980; 36998-5990; 42185-7039; 51552-1448; 52038-171; 69037-0074; 71052-043; 16714-034; 16714-035; 16714-355; 16714-356; 35208-031; 35208-032; 0121-1598; 42571-331; 43547-221; 43547-222; 50090-6378; 50228-190; 50228-471; 50268-470; 50474-002; 50474-598; 50474-599; 55111-182; 55111-183; 55154-4171; 55154-5782; 60505-3517; 60505-3518; 63323-400; 0378-5619; 65162-528; 65162-529; 68001-404; 68788-8254; 69102-107; 70518-1108; 70518-2109; 70518-3534; 70860-604; 71335-0694; 72572-360; 72865-189; 82009-124; 28877-5960; 68225-021; 13668-016; 14789-330; 16571-787; 16714-358; 0121-0799; 43547-224; 43547-346; 44567-502; 50090-3889; 50228-189; 60429-350; 60505-3280; 60687-249; 63629-9615; 65162-539; 68180-117; 70518-3769; 70860-603; 71930-062; 72205-097; 72789-152; 80705-100; 82009-121; 0904-7125; 62991-3189; 16571-788; 31722-574; 44567-500; 47133-575; 50090-2875; 50090-6086; 50383-241; 50405-301; 51079-821; 51672-4141; 55154-5699; 63629-7516; 0378-5617; 67457-255; 68001-114; 68001-402; 68180-115; 69102-108; 69339-157; 69367-333; 70518-0947; 70518-1796; 70518-1901; 70518-2230; 75834-245; 76282-247; 28877-0117; 28877-5970; 50683-0322; 62350-0059; 68554-0065; 14789-220; 16714-354; 31722-536; 39822-4000; 50228-472; 50405-300; 51655-325; 58118-1112; 61919-685; 67457-790; 70518-3770; 71335-0048; 0615-7976; 0615-7977; 72205-094; 72865-187; 72865-190; 0904-7123; 36998-5940; 36998-5970; 62331-010; 67835-0006; 27808-265; 31722-538; 0121-2397; 43485-101; 50474-001; 50474-594; 50474-595; 50474-596; 51991-651; 55111-248; 55154-3367
UNII 44YRR34555
Synonyms Levetiracetam | Etiracetam, S-isomer | Etiracetam, S isomer | S-isomer Etiracetam | Ucb L059 | Ucb-L059 | UCB 6474 | UCB-6474 | UCB6474 | Etiracetam, R-isomer | Etiracetam, R isomer | R-isomer Etiracetam | Etiracetam, (R)- | Keppra | Etiracetam | alpha-ethyl-2-oxo-1-Pyrrolidineacetamide | alpha ethyl 2 oxo 1 Pyrrolidineacetamide | Ucb L060 | Ucb-L060 | UcbL060
Chemical Information
Molecular Formula C8H14N2O2
CAS Registry Number 102767-28-2
SMILES CCC(C(=O)N)N1CCCC1=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cognitive disorder19.21.02.001; 17.03.03.0030.004190%
Procedural complication12.02.05.005--
Major depression19.15.01.0030.000517%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.000636%Not Available
Metabolic disorder14.11.01.0010.000397%Not Available
Purple glove syndrome24.04.05.010; 15.03.02.0130.000079%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000079%Not Available
Dysgraphia17.02.03.0060.000278%Not Available
Nail pigmentation23.02.05.0070.000079%Not Available
Dermatitis psoriasiform23.03.14.0040.000079%Not Available
Anogenital warts21.10.03.004; 16.26.01.003; 11.05.07.002; 07.19.04.002; 23.10.01.0030.000079%Not Available
Drug resistance08.06.01.0050.001264%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Recall phenomenon23.03.07.005; 12.02.06.001--
Freezing phenomenon17.01.05.0060.000119%Not Available
Adverse event08.06.01.010--Not Available
Appetite disorder14.03.01.004; 19.09.01.0020.000159%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.001033%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Cranial nerve disorder17.04.01.0010.000199%Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000397%Not Available
Eyelid disorder23.03.03.028; 06.08.03.010--Not Available
Foetal disorder18.03.02.0010.000079%Not Available
Impulse-control disorder19.18.01.0020.000199%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Libido disorder19.08.03.004; 21.03.02.0060.000119%Not Available
Intra-abdominal haemorrhage07.12.02.008; 12.01.17.011; 24.07.02.0350.000079%
Lactation disorder21.05.02.004; 18.06.02.0030.000238%
Learning disorder19.21.05.0010.000199%Not Available
Malnutrition14.03.02.004--Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 25 Pages